Molldrem et al. have reported a strong correlation between the presence of PR1-specific T cells and clinical responses after IFN-α and allogeneic BMT in CML patients, suggesting that CTLs against CML antigen play some role in eradicating CML-LSCs [91]. This evidence concerns the gene IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive.